Supply of Medicine and Medical / Surgical equipments : Dried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried factor VIII Fraction BP (Dried Recombinant\nAntihaemophilic Fraction) 200IU-350IU vial\nOR\nRecombinant Coagulation Factor VIII Ph Eur.\n200IU-350IU vial\nOR\nRecombinant Antihemophilic Factor USP 200IU-\n350IU vial\nOR\nDried Recombinant Antihaemophilic Fraction\nIP200IU-350IU vial\nEach vial to contain 200IU-350IU of concentrated,\npurified and viruses inactivated 3rd or 4th\ngeneration recombinant dried factor VIII Fraction\nBP, Ph Eur, USP or IP.\nNote:\n1. The item should be stable at temperature 2oC –\n8oC.\n2. The product should have minimum 24 months\nshelf life at the time of delivery to MSD.\n3. Tenderer should submit detailed specifications\nof the product offered.\n4. The product should ensure, at least two steps on\nvirus inactivation as recommended by\nWHO/US.FDA\n5. The purification process should be specified by\nthe manufacturer.\n6. Each batch should be certified as free from HIV\nhepatitis and other viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared by\nthe manufacturer. The test methods used should\nbe approved by WHO/US.FDA.\n8. Each vial to be supplied with suitable diluent.\n9. The product should be protected from light. etc .

STATE PHARMACEUTICALS CORPORATION OF SRI LANKA Sri Lanka has Released a tender for Supply of Medicine and Medical / Surgical equipments : Dried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried factor VIII Fraction BP (Dried Recombinant\nAntihaemophilic Fraction) 200IU-350IU vial\nOR\nRecombinant Coagulation Factor VIII Ph Eur.\n200IU-350IU vial\nOR\nRecombinant Antihemophilic Factor USP 200IU-\n350IU vial\nOR\nDried Recombinant Antihaemophilic Fraction\nIP200IU-350IU vial\nEach vial to contain 200IU-350IU of concentrated,\npurified and viruses inactivated 3rd or 4th\ngeneration recombinant dried factor VIII Fraction\nBP, Ph Eur, USP or IP.\nNote:\n1. The item should be stable at temperature 2oC –\n8oC.\n2. The product should have minimum 24 months\nshelf life at the time of delivery to MSD.\n3. Tenderer should submit detailed specifications\nof the product offered.\n4. The product should ensure, at least two steps on\nvirus inactivation as recommended by\nWHO/US.FDA\n5. The purification process should be specified by\nthe manufacturer.\n6. Each batch should be certified as free from HIV\nhepatitis and other viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared by\nthe manufacturer. The test methods used should\nbe approved by WHO/US.FDA.\n8. Each vial to be supplied with suitable diluent.\n9. The product should be protected from light. etc . in Pharmaceuticals. The tender was released on Dec 27, 2024.

Country - Sri Lanka

Summary - Supply of Medicine and Medical / Surgical equipments : Dried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried Recombinant Factor VIII Fraction 200IU-\n350IU vial\nDried factor VIII Fraction BP (Dried Recombinant\nAntihaemophilic Fraction) 200IU-350IU vial\nOR\nRecombinant Coagulation Factor VIII Ph Eur.\n200IU-350IU vial\nOR\nRecombinant Antihemophilic Factor USP 200IU-\n350IU vial\nOR\nDried Recombinant Antihaemophilic Fraction\nIP200IU-350IU vial\nEach vial to contain 200IU-350IU of concentrated,\npurified and viruses inactivated 3rd or 4th\ngeneration recombinant dried factor VIII Fraction\nBP, Ph Eur, USP or IP.\nNote:\n1. The item should be stable at temperature 2oC –\n8oC.\n2. The product should have minimum 24 months\nshelf life at the time of delivery to MSD.\n3. Tenderer should submit detailed specifications\nof the product offered.\n4. The product should ensure, at least two steps on\nvirus inactivation as recommended by\nWHO/US.FDA\n5. The purification process should be specified by\nthe manufacturer.\n6. Each batch should be certified as free from HIV\nhepatitis and other viruses.\n7. Anti viral test methods used for screening for\nHIV and Hepatitis viruses should be declared by\nthe manufacturer. The test methods used should\nbe approved by WHO/US.FDA.\n8. Each vial to be supplied with suitable diluent.\n9. The product should be protected from light. etc .

Deadline - Feb 06, 2025

GT reference number - 100578607

Product classification - Pharmaceutical products